Featured
Last news
CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness
With 20g of clean protein, 5g of creatine, and LactoSpore® probiotics, Empowr supports everyday strength, mental energy and digestive balance without dairy or added sugar. Simple, functional nutrition for modern living.
Black Book Research Releases "France: State of Acute Care EHR and Digital Health 2026"
France country extract from the 2026 Black Book of Global Digital Healthcare IT highlights procurement "proof points" shaping hospital DPI/EHR modernization through 2030: interoperability execution, Ségur-linked timing, GHT governance, regulated hosting (HDS), and cyber-resilience contracting
Karviva and Founder Dr. Angela Zeng Recognized by Missouri Agriculture as Brand Gains National Editorial Attention and Expands Retail Footprint
SAINT LOUIS, MI / ACCESS Newswire / February 26, 2026 / Karviva, the functional beverage company founded by nutritional scientist Dr. Angela Zeng, continues to gain momentum across retail and industry platforms, following recognition from the Missouri Department of Agriculture and its recent selection as one of RangeMe's Top 50 Brands in Food and Beverage. The milestones reflect growing demand for Karviva's science-backed wellness drinks and increasing interest from major retailers nationwide.
Dr. Angela Zeng's TEDx Talk on Supporting Children's Mental Health Without Medication Goes Live
SAINT LOUIS, MISSOURI / ACCESS Newswire / February 26, 2026 / Dr. Angela Zeng, scientist, entrepreneur, and founder of Karviva Wellness Beverages, has released her TEDx talk titled How to Support Your Child's Mental Health Without Medication, now officially live on YouTube. The talk, delivered at TEDxForbesParkSalon, has already surpassed 200,000 views since its publication on January 20, 2026.
Truly Good Foods Unveils Golden Hour(TM) Snack Bars
A Nut-Free, 110-Calorie Bar Designed for Today's On-the-Go Consumers
Forecast Change for The 2025/2026 Fiscal Year
DORTMUND, DE / ACCESS Newswire / February 26, 2026 / Following its elimination from the UEFA-Champions League play-offs yesterday evening and the resulting loss of planned earnings from this competition, Borussia Dortmund is now revising its earnings forecast published in the group management report as of June 30, 2025 to a consolidated net loss of between EUR -12,000 thousand and EUR -22,000 thousand (previously between EUR -5,000 thousand and EUR 5,000 thousand).
InterContinental Hotels Group PLC Announces Transaction in Own Shares - February 26
LONDON, UK / ACCESS Newswire / February 26, 2026 / The Company announces that on 25 February 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.
Scam centres 'destroying' Cambodia's economy, PM tells AFP
Cambodia's Prime Minister Hun Manet said on Wednesday that scam centres were destroying his country's economy and giving the nation a bad name -- pushing back on allegations of government connivance.
18 Egyptians missing after deadly boat capsize near Greece
Egypt said Wednesday that 18 of its citizens were still missing after a migrant boat capsized, killing four people, off the Greek island of Crete last week.
Bill Gates admits affairs but denies involvement in Epstein crimes
Bill Gates has admitted making a "huge mistake" in associating with Jeffrey Epstein, telling staff at his charity foundation that he had affairs with two Russian women but denying involvement in the disgraced financier's crimes.
Pope lines up trips to Central Africa, Algeria, Spain, Monaco
Pope Leo XIV will visit four African nations in April, the Vatican said Thursday, including Algeria -- the first time a pope will travel to the North African Muslim nation.
Australian police arrest two over alleged kidnapping, murder of grandfather
Australian detectives arrested two men Wednesday over the alleged kidnapping and murder of an elderly grandfather in a suspected case of mistaken identity.
Months after floods, Indonesian survivors frustrated by slow response
Normally, Indonesian mother-of-four Rauzah would cook a feast for her family to break their Ramadan fast. This year, she makes do as best she can in the orange tent where they have been sheltering for almost three months.
Canadians are choosing when to die, often with a smile
Jacques Poissant's suffering stopped the day he asked his daughter if it would be "cowardly to ask to be helped to die".
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.)NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this yearCompany expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with potential launch this yearPN-881 Phase 1 completion expected by mid-2026Pre-clinical pipeline expanded with novel wholly-owned candidates PN-477, an oral and s.c. triple GLP-GIP-GCG agonist and PN-458, an oral and s.c. dual GLP-GIP agonist, and PN-8047, an oral hepcidin functional mimeticCash, cash equivalents and marketable securities of $646 million as of December 31, 2025, anticipated to provide cash runway through at least end of 2028
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this yearCompany expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with potential launch this yearPN-881 Phase 1 completion expected by mid-2026
DirectTrust and CARIN Alliance Announce CARIN-CFA Accreditation Recognized by CMS as Evaluation Pathway for Participation in the Medicare App Library
Independent accreditation strengthens consumer trust in digital health applications and may support participation in CMS' Medicare App Library
VRCCO Invests in the Future of Veterinary Medicine Through Education-Driven Innovation
BEND, OREGON / ACCESS Newswire / February 25, 2026 / As the veterinary profession faces increasing demands, rapid medical advances, and nationwide workforce shortages, the Veterinary Referral Center of Central Oregon (VRCCO) is taking a proactive approach by strengthening the future of veterinary medicine through continuous education and hands-on professional development.
CBMJ Announces Launch of "Conservative Playbook" Podcast, Expanding Patriot.TV's High‑Growth Media Portfolio Ahead of Midterms
Navigating Contrasting Messaging by legacy media from Disney (DIS), Paramount Global (PARA), Comcast (CMCSA), Warner Bros. Discovery (WBD), and Newsmax (NMAX), Sinclair (SBGI), and Fox Corp. (FOX), Patriot.TV Provides Accurate Narrative regarding Elections.
Dolphin Expands Miami Footprint to Support Continued Growth Across Subsidiaries
Coral Gables office expansion accommodates team growth at The Digital Dept., The Door and other Dolphin agencies
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a determination letter from the Hearings Panel (the "Panel") of The Nasdaq Stock Market ("Nasdaq") dated February 23, 2026, notifying the Company that the Panel determined to delist the Company's securities from Nasdaq, due to the Company's failure to satisfy the continued listing conditions as previously disclosed. As a result, the Company securities will be suspended from trading at the open of business on February 26, 2026, and delisted from Nasdaq after the completion of certain applicable process. The Company does not intend to request a review of such decision.
A Curtain Call for Reason: 'The Age of Something Other Than Reason' Stages the Absurdity of Modern American Culture
CLEVELAND, OHIO / ACCESS Newswire / February 25, 2026 / Poet Anthony Andricks will release The Age of Something Other Than Reason on March 10, a bold poetry collection structured like a play in three acts and an intermission. The book stages a sharply theatrical examination of contemporary American culture shaped by social media, misinformation, ideological extremism, advancing technology, and algorithm-driven outrage.
HUNGRY Merges with Canada's hungerhub to Form Scaled Cross-Border Workplace Food Platform
Combined company surpasses $110 million in annual revenue, marking early North American consolidation in a fragmented corporate dining market
Armanino Foods to Participate in Upcoming Investor Conferences
PLEASANTON, CA / ACCESS Newswire / February 25, 2026 / Armanino Foods of Distinction, Inc. (OTCQX:AMNF), a leading provider of pesto and specialty frozen foods for North American foodservice, retail, and industrial customers, today announced that management will participate in three upcoming investor conferences in Spring 2026: the Stifel Consumer Executive Summit, the iAccess Alpha Spring Conference, and the 38th Annual ROTH Conference.
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.
Burst Raises $3M To Help Retailers Maximize FSA/HSA Spend While Lowering Consumer Health Costs
Post-purchase integration drives up to 30% higher customer basket size without changing checkout flows.
Duly Surgeon First in Illinois to Use Tumor-Illuminating Technology for Ovarian Cancer Surgery
DOWNERS GROVE, IL / ACCESS Newswire / February 25, 2026 / Duly Health and Care this month announced that Dr. Sameer Sharma, a gynecologic oncologist at Duly Health and Care's Chicagoland medical group, DuPage Medical Group, Ltd., is the first physician in Illinois to perform ovarian cancer surgery using Cytalux, a newly approved imaging agent that causes cancerous tissue to "glow" - and can thus help surgeons see and remove tumors with greater precision.
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms
Zomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology
Partnership Expected to Accelerate System Placements and Support Recurring Consumables Revenue Growth
Who is the Best Plastic Surgeon in the Pacific Northwest?
The Best Plastic Surgeon in the Pacific Northwest is Dr. Sajan
InterContinental Hotels Group PLC Announces Transaction in Own Shares - February 25
LONDON, UK / ACCESS Newswire / February 25, 2026 / The Company announces that on 24 February 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.
Pentixapharm Receives FDA "Study May Proceed" Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
U.S. Investigational New Drug (IND) applications for radiotheranostic pair PentixaFor and PentixaTher became active following completion of the FDA 30-day review period.Proposed phase I/II trial designed to confirm the suitability of CXCR4-directed radiotherapy for bone marrow conditioning in patients undergoing stem cell transplant.Overall aim is to complement or reduce conventional chemotherapy for acute myeloid leukemia (AML) and multiple myeloma (MM) patients